{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T06:12:59Z","timestamp":1782454379467,"version":"3.54.5"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0227552","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T18:36:27Z","timestamp":1582310187000},"page":"e0227552","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":37,"title":["Overall survival and second primary malignancies in men with metastatic prostate cancer"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4088-8561","authenticated-orcid":true,"given":"Juha","family":"Meht\u00e4l\u00e4","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihong","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdravko","family":"Vassilev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Brobert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montse Soriano","family":"Gabarr\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4r","family":"Stattin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houssem","family":"Khanfir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,2,21]]},"reference":[{"key":"pone.0227552.ref001","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","article-title":"Skeletal Related Events, Bone Metastasis and Survival of Prostate Cancer: A Population Based Cohort Study in Denmark (1999 to 2007)","volume":"184","author":"M N\u00f8rgaard","year":"2010","journal-title":"J Urol"},{"key":"pone.0227552.ref002","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1200\/JCO.1989.7.5.590","article-title":"Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response","volume":"7","author":"I Tannock","year":"1989","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"pone.0227552.ref003","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"DP Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"pone.0227552.ref004","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1634\/theoncologist.8-2-161","article-title":"Clinical Approaches to Osseous Metastases in Prostate Cancer","volume":"8","author":"MJ Morris","year":"2003","journal-title":"The Oncologist"},{"key":"pone.0227552.ref005","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3816\/CGC.2003.n.011","article-title":"Ten-year survival in patients with metastatic prostate cancer","volume":"2","author":"CM Tangen","year":"2003","journal-title":"Clin Prostate Cancer"},{"key":"pone.0227552.ref006","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer","volume":"369","author":"C Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"pone.0227552.ref007","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in Metastatic Prostate Cancer before Chemotherapy","volume":"371","author":"TM Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"pone.0227552.ref008","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","article-title":"Survival with Newly Diagnosed Metastatic Prostate Cancer in the \u201cDocetaxel Era\u201d: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK\/06\/019)","volume":"67","author":"ND James","year":"2015","journal-title":"Eur Urol"},{"key":"pone.0227552.ref009","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy","volume":"368","author":"CJ Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"pone.0227552.ref010","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1056\/NEJM199410133311507","article-title":"Management of cancer of the prostate","volume":"331","author":"WJ Catalona","year":"1994","journal-title":"N Engl J Med"},{"key":"pone.0227552.ref011","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.eururo.2006.08.043","article-title":"Antiandrogens in the treatment of prostate cancer","volume":"51","author":"MP Wirth","year":"2007","journal-title":"Eur Urol"},{"key":"pone.0227552.ref012","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(00)02163-2","article-title":"Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists\u2019 Collaborative Group","volume":"355","year":"2000","journal-title":"Lancet Lond Engl"},{"key":"pone.0227552.ref013","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1097\/01.ju.0000118294.88852.cd","article-title":"Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era","volume":"171","author":"MG Oefelein","year":"2004","journal-title":"J Urol"},{"key":"pone.0227552.ref014","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review: The Epidemiology of CRPC","volume":"65","author":"M Kirby","year":"2011","journal-title":"Int J Clin Pract"},{"key":"pone.0227552.ref015","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.eururo.2007.09.002","article-title":"EAU Guidelines on Prostate Cancer","volume":"53","author":"A Heidenreich","year":"2008","journal-title":"Eur Urol"},{"key":"pone.0227552.ref016","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"HI Scher","year":"2008","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"pone.0227552.ref017","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1200\/JCO.2008.19.9810","article-title":"Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916","volume":"27","author":"M Hussain","year":"2009","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"pone.0227552.ref018","first-page":"1475","article-title":"Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival","volume":"31","author":"E Bournakis","year":"2011","journal-title":"Anticancer Res"},{"key":"pone.0227552.ref019","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s00259-004-1479-z","article-title":"Bone scintigraphy predicts the risk of spinal cord compression in hormone-refractory prostate cancer","volume":"31","author":"V Soerdjbalie-Maikoe","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"pone.0227552.ref020","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1081\/CNV-200039643","article-title":"Study of hormone refractory prostate cancer: hospital care and palliative care resource use at a VA medical center","volume":"22","author":"SS Hwang","year":"2004","journal-title":"Cancer Invest"},{"key":"pone.0227552.ref021","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/sj.bjc.6602767","article-title":"Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease","volume":"93","author":"A Berruti","year":"2005","journal-title":"Br J Cancer"},{"key":"pone.0227552.ref022","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.urology.2008.07.062","article-title":"Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan","volume":"73","author":"T Inoue","year":"2009","journal-title":"Urology"},{"key":"pone.0227552.ref023","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3747\/co.v17i2.482","article-title":"A review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital","volume":"17","author":"SN Chin","year":"2010","journal-title":"Curr Oncol Tor Ont"},{"key":"pone.0227552.ref024","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and Increased Survival in Metastatic Prostate Cancer","volume":"364","author":"JS de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"pone.0227552.ref025","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/(SICI)1097-0142(19970415)79:8<1600::AID-CNCR24>3.0.CO;2-0","article-title":"Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma","volume":"79","author":"AI Neugut","year":"1997","journal-title":"Cancer"},{"key":"pone.0227552.ref026","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ijrobp.2006.02.044","article-title":"Induced second cancers after prostate-cancer radiotherapy: No cause for concern?","volume":"65","author":"DJ Brenner","year":"2006","journal-title":"Int J Radiat Oncol"},{"key":"pone.0227552.ref027","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.radonc.2013.12.012","article-title":"Second primary cancers after radiation for prostate cancer: A systematic review of the clinical data and impact of treatment technique","volume":"110","author":"L Murray","year":"2014","journal-title":"Radiother Oncol"},{"key":"pone.0227552.ref028","doi-asserted-by":"crossref","first-page":"i851","DOI":"10.1136\/bmj.i851","article-title":"Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis","author":"CJD Wallis","year":"2016","journal-title":"BMJ"},{"key":"pone.0227552.ref029","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1093\/ije\/dys068","article-title":"Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0","volume":"42","author":"M Van Hemelrijck","year":"2013","journal-title":"Int J Epidemiol"},{"key":"pone.0227552.ref030","unstructured":"Engholm G, Ferlay J, Christensen N, et al. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 7.3. Association of the Nordic Cancer Registries. Danish Cancer Society. 2016. http:\/\/www.ancr.nu (accessed 29 Mar 2017)."},{"key":"pone.0227552.ref031","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1002\/cncr.27672","article-title":"Primary cancers before and after prostate cancer diagnosis: Other Primary Cancers & Prostate Cancer","volume":"118","author":"M Van Hemelrijck","year":"2012","journal-title":"Cancer"},{"key":"pone.0227552.ref032","doi-asserted-by":"crossref","first-page":"e102596","DOI":"10.1371\/journal.pone.0102596","article-title":"Incidence of Second Malignancies for Prostate Cancer","volume":"9","author":"M Van Hemelrijck","year":"2014","journal-title":"PLoS ONE"},{"key":"pone.0227552.ref033","volume-title":"Radiobiology for the radiologist","author":"EJ Hall","year":"2012"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0227552","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,28]],"date-time":"2021-02-28T12:06:13Z","timestamp":1614513973000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0227552"}},"subtitle":[],"editor":[{"given":"Vincenza","family":"Conteduca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,2,21]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0227552","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,21]]}}}